Mivacurium chloride (Mivacron) is a new benzylisoquinolinium choline-like diester neuromuscular blocking drug with an onset of action at equipotent doses that is comparable to atracurium and vecuronium but slower than succinylcholine. MIVACRON (a mixture of three stereoisomers) binds competitively to cholinergic receptors on the
motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular
transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine. MIVACRON is a short-acting neuromuscular blocking agent indicated for inpatients and outpatients,
as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle
relaxation during surgery or mechanical ventilation.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 3.69 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | MIVACRON Approved UseMIVACRON is a short-acting neuromuscular blocking agent indicated for inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Launch Date1992 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
504 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/ |
0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
MIVACURIUM, CIS-CIS- plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2198 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/ |
0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
MIVACURIUM, CIS-TRANS- plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
4486 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/ |
0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
MIVACURIUM, TRANS-TRANS- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.295 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/ |
0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
MIVACURIUM, CIS-CIS- plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.178 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/ |
0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
MIVACURIUM, CIS-TRANS- plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.932 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/ |
0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
MIVACURIUM, TRANS-TRANS- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
28.5 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/ |
0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
MIVACURIUM, CIS-CIS- plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/ |
0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
MIVACURIUM, CIS-TRANS- plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.4 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9054251/ |
0.15 mg/kg single, intravenous dose: 0.15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
MIVACURIUM, TRANS-TRANS- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
0.2 mg/kg single, intravenous Recommended Dose: 0.2 mg/kg Route: intravenous Route: single Dose: 0.2 mg/kg Sources: Page: p.12 |
unhealthy Health Status: unhealthy Condition: Skeletal muscle relaxation during surgery Sources: Page: p.12 |
Other AEs: Anaphylactic reaction... Other AEs: Anaphylactic reaction (grade 3-5) Sources: Page: p.12 |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Anaphylactic reaction | grade 3-5 | 0.2 mg/kg single, intravenous Recommended Dose: 0.2 mg/kg Route: intravenous Route: single Dose: 0.2 mg/kg Sources: Page: p.12 |
unhealthy Health Status: unhealthy Condition: Skeletal muscle relaxation during surgery Sources: Page: p.12 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Potentiation of mivacurium by rocuronium is age- and time-dependent: a study in children, adolescents, and young and elderly adults. | 1997 Jul |
|
| Is succinylcholine after pretreatment with d-tubocurarine and lidocaine contraindicated for outpatient anesthesia? | 2000 Aug |
|
| Nondepolarizing neuromuscular blockers inhibit the serotonin-type 3A receptor expressed in Xenopus oocytes. | 2000 Feb |
|
| Prevention of succinylcholine-induced fasciculation and myalgia: a meta-analysis of randomized trials. | 2005 Oct |
|
| Naturally occurring mutation Leu307Pro of human butyrylcholinesterase in the Vysya community of India. | 2006 Jul |
|
| Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade. | 2006 Sep |
|
| Fresh frozen plasma transfusion for reversal of prolonged post-anaesthesia apnoea. | 2008 Apr |
Sample Use Guides
Adults
Initial Doses
Doses of 0.15 mg/kg administered over 5 to 15 seconds, 0.20 mg/kg administered over 30 seconds,
or 0.25 mg/kg administered in divided doses (0.15 mg/kg followed in 30 seconds by 0.10 mg/kg) are
recommended for facilitation of tracheal intubation for most patients
Route of Administration:
Intravenous
In Vitro Use Guide
Curator's Comment: Left atrial preparations were stimulated by electrical field stimulation using a bipolar platinum electrode, and the effects of cumulative concentrations of nondepolarizing neuromuscular blocking agents on the developed force in the presence and absence of propranolol (10(-8) M) and desipramine (10(-7) M) were recorded.
The left or right atria of rats were removed and suspended in organ baths. Mivacurium was added cumulatively (10(-9)-10(-5) M) in the presence and absence of the nonselective β-blocker propranolol (10(-8) M) and the noradrenaline reuptake inhibitor desipramine (10(-7) M), and heart rate changes were recorded in spontaneously beating right atria. Mivacurium increased developed force in a dose-dependent manner; the increases were significant at 10(-5) M concentration for mivacurium.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
M03AC10
Created by
admin on Sat Dec 16 16:08:27 GMT 2023 , Edited by admin on Sat Dec 16 16:08:27 GMT 2023
|
||
|
NCI_THESAURUS |
C66886
Created by
admin on Sat Dec 16 16:08:27 GMT 2023 , Edited by admin on Sat Dec 16 16:08:27 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
30077
Created by
admin on Sat Dec 16 16:08:27 GMT 2023 , Edited by admin on Sat Dec 16 16:08:27 GMT 2023
|
PRIMARY | RxNorm | ||
|
1822
Created by
admin on Sat Dec 16 16:08:27 GMT 2023 , Edited by admin on Sat Dec 16 16:08:27 GMT 2023
|
PRIMARY | |||
|
106791-40-6
Created by
admin on Sat Dec 16 16:08:27 GMT 2023 , Edited by admin on Sat Dec 16 16:08:27 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
133814-19-4
Created by
admin on Sat Dec 16 16:08:27 GMT 2023 , Edited by admin on Sat Dec 16 16:08:27 GMT 2023
|
PRIMARY | |||
|
DB01226
Created by
admin on Sat Dec 16 16:08:27 GMT 2023 , Edited by admin on Sat Dec 16 16:08:27 GMT 2023
|
PRIMARY | |||
|
7243
Created by
admin on Sat Dec 16 16:08:27 GMT 2023 , Edited by admin on Sat Dec 16 16:08:27 GMT 2023
|
PRIMARY | |||
|
C049430
Created by
admin on Sat Dec 16 16:08:27 GMT 2023 , Edited by admin on Sat Dec 16 16:08:27 GMT 2023
|
PRIMARY | |||
|
C83966
Created by
admin on Sat Dec 16 16:08:27 GMT 2023 , Edited by admin on Sat Dec 16 16:08:27 GMT 2023
|
PRIMARY | |||
|
5281042
Created by
admin on Sat Dec 16 16:08:27 GMT 2023 , Edited by admin on Sat Dec 16 16:08:27 GMT 2023
|
PRIMARY | |||
|
DTXSID6048333
Created by
admin on Sat Dec 16 16:08:27 GMT 2023 , Edited by admin on Sat Dec 16 16:08:27 GMT 2023
|
PRIMARY | |||
|
77D66S9Q93
Created by
admin on Sat Dec 16 16:08:27 GMT 2023 , Edited by admin on Sat Dec 16 16:08:27 GMT 2023
|
PRIMARY | |||
|
100000086141
Created by
admin on Sat Dec 16 16:08:27 GMT 2023 , Edited by admin on Sat Dec 16 16:08:27 GMT 2023
|
PRIMARY | |||
|
SUB03310MIG
Created by
admin on Sat Dec 16 16:08:27 GMT 2023 , Edited by admin on Sat Dec 16 16:08:27 GMT 2023
|
PRIMARY |
All of the following components must be present:
ACTIVE MOIETY
SALT/SOLVATE (PARENT)